Microbot Medical INC 8-K filings

Microbot Medical Inc. announced significant second-quarter growth with over 100% revenue and customer increase, driven by the Full Market Release of its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. has announced an addendum to its Chief Financial Officer's employment agreement, increasing her annual base salary.

Microbot Medical Inc. announced its CEO will present on endovascular robotics at the Society of Robotic Surgery annual meeting.

Microbot Medical Inc. announced over 100% revenue and new customer growth in Q2 2026, driven by the LIBERTY System's full market release and expanding sales territories.

Microbot Medical Inc. has entered into a strategic agreement with Sanmina Corporation to enhance manufacturing capacity for its LIBERTY Endovascular Robotic System, aiming to meet growing demand and reduce costs.

Microbot Medical received the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. has entered into a vendor agreement with Lovell Government Services to offer its LIBERTY Endovascular Robotic System to over 2,000 U.S. government facilities.

Microbot Medical Inc. announced its first Midwest-based account with a Michigan healthcare system for its LIBERTY Endovascular Robotic System, signaling continued U.S. market expansion.

Microbot Medical Inc. announced its LIBERTY Endovascular Robotic System has been adopted by its first North Carolina-based healthcare system, marking expanded geographic reach.

Microbot Medical Inc. announced it has received regulatory approval from Israel's Ministry of Health to market and commercialize its LIBERTY Endovascular Robotic System in the country.

Microbot Medical Inc. announced a conference call for May 18th to discuss the LIBERTY Endovascular Robotic System's progress and address recent third-party article inaccuracies.

Microbot Medical Inc. announced that its second quarter 2026 revenue has already surpassed first quarter revenue, driven by the accelerated utilization and adoption of its LIBERTY Endovascular Robotic System following its full market release.

Microbot Medical Inc. announces significant physician and hospital executive interest in its LIBERTY Endovascular Robotic System following its full market release, securing new accounts in key territories.

Microbot Medical Inc. highlights how updated occupational protection guidelines from leading radiology societies could enhance the commercial prospects of its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. announced it will showcase commercial achievements for its LIBERTY Endovascular Robotic System's Full Market Release at the 25th Annual Needham Virtual Healthcare Conference.

Microbot Medical announces the full market release of its LIBERTY Endovascular Robotic System in the U.S. following a successful limited market release.

Microbot Medical Inc. has filed a Form 8-K to provide details on its updated At-the-Market (ATM) Offering Program, allowing for potential sales of up to $39.2 million in common stock.

Emory Healthcare successfully completed robotic peripheral endovascular procedures using Microbot Medical's LIBERTY Endovascular Robotic System for BPH and liver cancer.

Microbot Medical announced the publication of its LIBERTY ACCESS PVI Pivotal Study in the Journal of Vascular and Interventional Radiology, a significant validation for its robotic system.

Microbot Medical Inc. announced its participation in the Roth Annual Growth Conference and confirmed its LIBERTY Endovascular Robotic System is on target for full market release in April 2026.

Microbot Medical Inc. announced its LIBERTY Endovascular Robotic System aligns with a new American Medical Association policy aimed at protecting healthcare professionals from ionizing radiation.

Microbot Medical Inc. announced continued operational and commercial stability in the U.S. and Israel despite current geopolitical events, maintaining its focus on the LIBERTY Endovascular Robotic System's market release.

Microbot Medical Inc. announced significant compensation increases and a special bonus for its key executives.

Microbot Medical Inc. announced that Tampa General Hospital is the first health system in Florida to adopt its LIBERTY Endovascular Robotic System, following recent FDA clearance.

Microbot Medical Inc. announced its CEO, Harel Gadot, will be a featured panelist at The Surgical Disruptive Technology Summit, highlighting the LIBERTY Endovascular Robotic System.

Microbot Medical's LIBERTY Endovascular Robotic System was prominently featured at the International Symposium on Endovascular Therapy (ISET) conference, highlighting its commercial traction and future role.

Microbot Medical Inc. announced its participation in the Society of Interventional Oncology annual meeting to accelerate commercial adoption of its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. reaffirms its 2025 achievements, including FDA clearance and initial LIBERTY system adoption, and announces key operational and commercial milestones for 2026, including a Full Market Release.

Microbot Medical announced Emory University Hospital is the first in the world to adopt its LIBERTY Endovascular Robotic System for patient care, marking a significant commercial milestone.

Microbot Medical Inc. announced the limited commercial availability of its LIBERTY Endovascular Robotic System in the U.S., marking a significant step in its commercialization strategy.